

Research Article**Frequency of Factors Leading To Multidrug Resistant Tuberculosis**

**¹Samina Waseem, ²Mustansar Billah
and ³Rana Taseer Ahmad**

¹Assistant Professor Department of Community Medicine
Sheikh Zayed Medical College/Hospital Rahim Yar Khan

²Assistant Professor Department of Community Medicine
Multan Medical & Dental College, Multan

³House Officer DHQ Teaching Hospital, D.G Khan

ABSTRACT

Objective:The objective of this study is “to determine the frequency of factors leading to Multidrug resistance tuberculosis, in patients presenting at Sheikh Zayed Hospital Rahim Yar Khan”.

Material and methods:This cross sectional was conducting at Department of Pulmonology, Sheikh Zayed Medical College / Hospital Rahim Yar Khan from March 2017 to September 2017. Total 126 patients with MDR-TB were selected for this study. Association of reasons for interruption of ATT course, inadequate chemotherapy, under whose prescription ATT used previously and Previous H/O of taking ATT with gender, age and area of residence was assessed.

Results:Total 126 patients with MDR-TB were included in this study. Minimum age of the patients was 20 years and maximum age of the patients was 60 years. Mean age of the patients was 39.44 ± 9.043 .

Most 65 (51.6%) of the patients with MDR-TB belonged to age group 31-40 years and 74 (58.7%) were male and 52 (41.3%) were female.

Conclusion:Results of this study revealed that the most common age group affected with MDR-TB was 31-40 years. Male were more victim as compare to female. Mostly patients reported with MDR-TB have previous history of taking ATT under.

Keywords: MDR-TB. Multi-drug resistant tuberculosis. Factors, Primary MDR-TB, DOTS

INTRODUCTION

Tuberculosis is a specific infectious disease caused by Mycobacterium Tuberculosis, primarily affect lungs. It can also affect intestine, meninges, bones and joints, lymph nodes and other tissues of body. The disease is usually chronic with varying clinical manifestations. Approximately one third of the world population having latent tubercle bacilli infection. Around 8 million new cases of active disease develop each year and 3 million people die.¹ In Pakistan its incidence is estimated to be 171/100,000 population.² Besides high incidence of tubercle bacilli in Pakistan, prevalence of multi drug resistant strains is also a cause of great concern.³Multi Drug Resistant

Tuberculosis (MDR TB) is defined as “simultaneous resistance of mycobacterium tuberculosis to both isoniazid (INH) and rifampicin (RIF) with or without resistance to other anti tuberculosis drugs.⁴ Patients infected with MDR strains are not only difficult to cure but also more likely to remain source of infection for a longer period of time than those with drug susceptible organisms.⁵ At any given time about 630,000 people in the world are thought to carry strains of M. tuberculosis showing resistance to the two drugs that are currently the most effective against tuberculosis (TB): isoniazid and rifampicine.⁶ So far, the magnitude of the problem

posed by multidrug resistant TB (MDR TB) has been estimated in about two thirds of all countries worldwide through disease surveillance and surveys. Each year, as more studies are conducted, new hot spots of MDR TB are documented.⁷

Tuberculosis continues to be a global public health problem. Drug resistance and obstacles to successful directly observed therapy short course (DOTS) impede disease control. Among patients being retreated for TB because of initial treatment failure, default from initial treatment or relapse following initial treatment, drug resistance is common and retreatment outcomes are inferior.

Drug resistance is entirely a man made problem and develops in otherwise treatable TB when the course of treatment is interrupted and the levels of drug in the body are insufficient to kill 100% of bacteria. This can happen due to number of reasons like inadequate chemotherapy, repeated intermittent courses of ATT, unsupervised treatment by general practioner during initial course of ATT. Exposure to single drug due to irregular drug supply and poor compliance of patient suppresses the growth of bacilli susceptible to that drug but permits the multiplication of drug resistant organisms.⁸

Prevalence of some risk factors for multidrug resistant tuberculosis as in a study conducted at Tertiary Care Hospital Peshawar are as previous history of taking ATT / repeated and intermittent courses of ATT(20% had undertaken ATT course once, 53.3% twice and 26.7% thrice in past) , inadequate chemotherapy(43.3%), family history of tuberculosis(23.3%), and reasons for interruption of their treatment e.g non affordability and having side effects(46.2% each) and feeling of no improvement(7.6%).⁹

Isoniazid is one of the most effective and specific agent for the treatment of the disease caused by Mycobacterium Tuberculosis. It is the corner stone of the modern short course chemotherapy for tuberculosis and also widely used to treat latent mycobacterium tuberculosis infection to prevent the active disease and the subsequent TB transmission.¹⁰ Patients infected with a mycobacterium spp. Strain resistant to INH and RIF, which defines a MDR TB strain, do not

respond to WHO standardized directly observed short course chemotherapy and require longer, more toxic and more expensive treatment. The only way to prevent TB entirely is to effectively treat the active cases, so as to stop the transmission of this infection in the community.^{11,12}

The increasing prevalence of infection with drug resistant Mycobacterium tuberculosis represents a global public health emergency as there is minimum work at local level. Determination of factors for MDR TB will help to stop the transmission of this infection in the community which will reduce the economical burden of community and as well as complication or side effects of the treatment would also be decreased.

OPERATIONAL DEFINITIONS

Factor:Is any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease.

Inadequate Chemotherapy: Inadequate chemotherapy was labeled when there is administration of lower doses of ATT used or failure to complete the whole course of treatment.

Repeated or incomplete courses of ATT: Patient took treatment of TB once, twice or more and not complete the established course of treatment.

Non Affordability: It was labeled when there is interruption of ATT due to non affordability.

Side effects: It was labeled when there is interruption of ATT due to having side effects like vomiting (2 or 3 times a day) for at least one day

MATERIAL AND METHODS

This cross sectional was conducting at Department of Pulmonology, Sheikh Zayed Medical College / Hospital Rahim Yar Khan from March 2017 to September 2017. Total 126 patients with MDR-TB were selected for this study.

Inclusion criteria:All the patients of either age and sex from Pulmonology Department SZH, Rahim Yar Khan suffering from tuberculosis, whose AFB culture and sensitivity report revealed INH and RIF both resistance.

Exclusion criteria:All patients from Pulmonology Department SZH, Rahim Yar Khan suffering from tuberculosis whose AFB culture and sensitivity report revealed Mono drug resistant TB or Poly drug resistant TB but not Multi Drug Resistant TB. All those patients whose culture and sensitivity report was awaited or not available at time of interview was also be excluded.

DATA COLLECTION PROCEDURE:

Data was collected on a pre-designed pre-tested questionnaire. The data was regarding age, gender, family history of TB collected. History of tuberculosis in past, repeated or incomplete courses of ATT, inadequate chemotherapy, non-affordability and side effects were also be recorded. In patients having past history of TB, further information like under which supervision (DOTS, general physician, chest consultant, others) ATT was used, were also be recorded.

DATA ANALYSIS: The data were entered and analyzed in SPSS version 16. Mean and Standard Deviation was measured for quantitative data like age. Qualitative data were presented in percentages such as, gender, interruption due to side effects, non affordability, inadequate chemotherapy and repeated and incomplete courses of ATT. Stratification with respect to age, gender and area of residence was done. Post stratification, chi square test was applied. P value less than and equal to 0.05 was taken as significant.

Table 1 Association of reasons for interruption of ATT course, inadequate chemotherapy, under whose prescription ATT used previously and Previous H/O of taking ATT with gender

Variables	Gender		Total	P. value
	Male (%)	Female (%)		
Reasons for interruption of ATT course				0.761
Non-affordability	37 (61.67)	23 (38.33)	60 (47.62)	
Side effects	33 (56.9)	25 (43.1)	58 (38.1)	
Not improving	4 (50)	4 (50)	8 (6.35)	
Total	74 (58.53)	52 (41.27)	126	
inadequate chemotherapy				0.519

RESULTS

Total 126 patients with MDR-TB were included in this study. Minimum age of the patients was 20 years and maximum age of the patients was 60 years. Mean age of the patients was 39.44 ± 9.043. Patients were divided into different age group. Out of 126 MDR-TB patients 74 (58.7%) were male and 52 (41.3%) were female. Non-affordability was the reason in 60 (47.62) patients of which 37 (61.67%) were male and 23 (38.33%) were female. Side effects of ATT course was the reason for interruption of ATT course in 58 (38.1%) patients, of which 33 (56.9%) patients were male and 25 (43.1%) patients were female. Not improving was the reason of interruption of ATT course in 8 (6.35%) patients, 50% patients were male and 50% patients were female. Statistically insignificant association of reasons for interruption of ATT course with gender was noted with p value 0.761. Statistically insignificant association of reasons for interruption of ATT course, inadequate chemotherapy, Under whose prescription ATT used previously and Previous H/O of taking ATT with gender was noted. (Table 1)

Table No. 2 showing association of reasons for interruption of ATT course, inadequate chemotherapy, under whose prescription ATT used previously and Previous H/O of taking ATT with age groups. Table No. 3 showing association of reasons for interruption of ATT course, inadequate chemotherapy, under whose prescription ATT used previously and Previous H/O of taking ATT with area of residence.

Frequency of Factors Leading To Multidrug Resistant Tuberculosis

Yes	29 (58)	21 (42)	50 (39.68)	
No	45 (59.21)	31 (40.79)	76 (60.32)	
Total	74 (58.73)	52 (41.27)	126	
Under whose prescription ATT used previously				
DOTS	36 (65.45)	19 (34.55)	55 (4.37)	0.261
GP	34 (56.67)	26 (43.33)	60 (47.62)	
Chest Consultant	4 (40)	6 (60)	10 (7.94)	
Others	0	1 (100)	1 (0.79)	
Total	74 (58.73)	52 (41.27)	126	
Previous H/O of taking ATT				
Yes	63	44	107	0.564
No	11	8	19	
Total	74	52	126	

Table 2 Association of reasons for interruption of ATT course, inadequate chemotherapy, under whose prescription ATT used previously and Previous H/O of taking ATT with age groups

Variables	Age Group				Total	P. value
	20-30 (%)	31-40 (%)	41-50 (%)	51-60 (%)		
Reasons for interruption of ATT course						
Non-affordability	5 (8.33)	28 (46.67)	16 (26.67)	11 (18.33)	60 (47.62)	0.338
Side effects	10 (17.24)	32 (55.17)	9 (15.52)	7 (12.07)	58 (46.04)	
Not improving	0	5 (62.5)	1 (12.5)	2 (25)	8 (6.35)	
Total	15 (11.9)	65 (51.59)	26 (20.63)	20 (15.87)	126	
inadequate chemotherapy						
Yes	8 (16)	24 (48)	12 (24)	6 (12)	50 (39.68)	0.455
No	7 (9.21)	41 (53.95)	14 (18.42)	14 (18.42)	76 (60.32)	
Total	15 (11.90)	65 (51.59)	26 (20.63)	20 (15.87)	126	
Under whose prescription ATT used previously						
DOTS	7 (12.73)	25 (45.45)	14 (25.45)	9 (16.36)	55 (43.65)	0.602
GP	6 (10)	35 (58.33)	9 (15)	10 (16.67)	60 (47.62)	
Chest Consultant	2 (20)	5 (50)	2 (20)	1 (10)	10 (7.94)	
Others	0	0	1 (100)	0	1 (0.79)	
Total	15 (11.90)	65 (51.59)	26 (20.63)	20 (15.87)	126	
Previous H/O of taking ATT						
Yes	14	58	21	14	107	0.133
No	1	7	5	6	19	
Total	15	65	26	20	126	

Table 3: Association of reasons for interruption of ATT course, inadequate chemotherapy, under whose prescription ATT used previously and Previous H/O of taking ATT with area of residence

Variables	Area of residence		Total	P. value
	Rural n (%)	Urban n (%)		
Reasons for interruption of ATT course				
Non-affordability	38 (63.33)	22 (36.67)	60 (47.62)	0.374
Side effects	35 (60.34)	23 (39.66)	58 (46.03)	
Not improving	3 (37.5)	5 (62.5)	8 (6.35)	
Total	76 (60.32)	50 (39.68)	126	
inadequate chemotherapy				
Yes	28 (56)	22 (44)	50 (39.68)	0.268
No	48 (63.16)	28 (36.84)	76 (60.32)	
Total	76 (60.32)	50 (39.68)	126	
Under whose prescription ATT used previously				
DOTS	33 (60)	22 (40)	55 (43.65)	0.168
GP	39 (65)	21 (35)	60 (47.62)	
Chest Consultant	3 (30)	7 (70)	10 (7.94)	
Others	1 (100)	0	1 (0.79)	
Total	76 (60.32)	50 (39.68)	126	
Previous H/O of taking ATT				
Yes	65	42	107	0.815
No	11	8	19	
Total	76	50	126	

DISCUSSION

MDR-TB is an increasing global problem arising from a combination of physicians’ error and patients’ noncompliance during treatment of susceptible tuberculosis. Wild strains of Mycobacterium tuberculosis that have not been exposed to anti-tuberculosis drugs are almost never resistant.⁸In present study mean age of the patients with MDR-TB was 39.44 ± 9.043. Similar mean age (34.2 ± 15.3 years) of the

patients with MDR-TB was reported by Wahab et al⁸ in their study conducted at Peshawar. Results of Present study revealed that out of 126 patients with MDR-TB, the most common (51.6%) age group was 31-40 years. In one study by Wahab et al,¹ the most common age group of patients with MDR-TB was 20-40 years which are similar with our study. Faustini et al¹³ reported that most of the patients with MDR-TB was below 65 years. In another study Moniruzzaman et al,¹⁴ the most

common (46%) age group of patients with MDR-TB was 21-40 year. These findings are also in favor of my study.

In present study out of 126 patients with MDR-TB male are more common as compare to female 58.7% vs 41.3%. Male patients with MDR-TB are prominent in our study. Faustini et al¹³ determined the risk factors for MDR-TB in six countries of Europe and found that MDR-TB patients were more likely to be male. Findings of this study are similar with present study. Moniruzzaman et al¹⁴ also reported 55% male and 45% female patients with MDR-TB in their study. These findings are also comparable with my study. In another study, Mulu et al¹⁵ reported male predominance (57.5% vs 42.5%) in patients with MDR-TB. These results are similar with my study.

In present study 69.8% patients were un-educated, 19% patients were under metric and 11.1% were above metric. Wahab et al⁸ reported in their study, 70% patients as un-educated, 26.7% under metric and 3.3% patients as above metric. Results of this study are in favor of our study. In another study by Moniruzzaman et al,¹⁴ among the 295 patients with MDR-TB 58% patients were secondary or below secondary and 42% patients were above secondary.

In present study 59.5% patients were laborer, 7.9% were students, 10.3% were government employee, 3.2% were house wife and 19% patients belonged to different other occupations. In one study conducted at Peshawar by Wahab et al,⁸ it was noted that 64.7% patients with MDR-TB were laborer followed by 5.8% were students, 11.8% were Govt. employee and 17.7% patients were belonged to different other profession. These findings are comparable with my study. Mulu et al¹⁵ reported in his study that 8.5% patients with MDR-TB were students and 14.4% were employee and 19% were laborer. These results were also in favour of our study.

In my study 60.3% patients belonged to rural area and 39.7% patients belonged to urban area. Similar results were reported by Mulu et al¹⁵ in their study. They found 25.5% patients belonged rural area and 75.5% patients belonged to urban

area. Results of another study by Li W-B¹⁶ were also in favour of my study. He noted 68.78% patients belonged to rural area and 39.22% patients belonged urban area. In study of Tadesse F et al¹⁷ 82.2% were urban residents whereas 17.8% came from rural areas.

In my study total 84.9% patients were found with previous history of taking ATT. In one study by Tadesse F,¹⁷ among the MDR-TB cases, 97% have previously been treated for TB. Results of this study are comparable with our study. But Baliza et al¹⁸ found 50% patients with previous history of ATT used which is in contrast with my study.

Total 43.7% patients taking ATT under DOT previously, 47.6% patients used ATT prescribed by GP, only 7.9% patients taking ATT on prescription of chest consultant and 0.8% patient taking ATT by some other sources. Similar results were reported by Wahab et al,⁸ they reported that 40% patients taking ATT under DOT, 46.7% by GP, 6.7% by Physician.

CONCLUSION

Results of this study revealed that the most common age group affected with MDR-TB was 31-40 years. Male were more victim as compare to female. Mostly patients reported with MDR-TB have previous history of taking ATT under.

REFERENCES

1. Dye C, Williams BG. Criteria for the control of drug resistant tuberculosis. Proc Natl Acad Sci USA 2000;97:8180-5.
2. World Health Organization. Global tuberculosis control; surveillance, planning, financing. WHO report, Geneva: World Health Organization, 2003 .
3. Matter TO. Surveillance of tuberculosis transmission by chromosomal DNA fingerprinting. Infect Dis J P 1997;4:3-5.
4. Mahmood A. Multi- drug resistant tuberculosis. J Pak Med Assoc 2001;51: 204-5.
5. Green E, Nchbeleng, M, De villiers, BR, Sein P P, Lestoalo T, Hoosen A A, Bessong P O, Ndep R N. Drug susceptibility patterns

- of *Mycobacterium tuberculosis* in Mpumalanga Province, South Africa: Possible Guiding Dising of Retreatment Regimn. *J Health Poul Nuter* 2010;28:7–13.
6. *Global tuberculosis control* Geneva: World Health Organization; 2012 (WHO/HTM/TB/2012.6).
 7. Zignol M, van Gemert W, Falzon D, Sismondì's C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. *Bull World Health Organ.*2012;90:111–119 D.doi:10.2471/BLT.11.092585.
 8. The WHO/IUATLD.Global project on anti-tuberculosis drug resistant surveillance: anti – tuberculosis resistance in the world. prevalence trends: report no.2: Geneva: World Health Organization, 2000:20–5.
 9. Fazli W, Sadia A, Naveed k. Risk factors for Multi-drug Resistant Tuberculosis in patients at Tertiary Care Hospital, Peshawar. *JCPSP* 2009;19(3):162–164.
 - 10.Hu, Y, Hofner, S, Jiang, Wei Wei, Xu, B. Extensive transmission of isoniazid resistant *M.tuberculosis* and its association with increased multidrug resistant TB in two rural counties of eastern China: a molecular epidemiological study. *BML infectious diseases* 2010;10:43-49.
 - 11.Hussain F. Drug resistant TB. *Park Jchest Med* 2001;7 (suppl):17–8.Sandhu GK. Tuberculosis: Current Situation, Challenges and Overview of its ControlPrograms in India. *J Glob Infect Dis.* 2011;3(2):143–50.
 - 12.Sandhu GK. Tuberculosis: Current Situation, Challenges and Overview of its Control Programs in India. *J Glob Infect Dis.* 2011;3(2):143–50.
 - 13.Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. *Thorax.* 2006 Feb;61(2):158–63.
 - 14.Moniruzzaman A, Elwood RK, Schulzer M, FitzGerald JM. A population-based study of risk factors for drug-resistant TB in British Columbia. *The International Journal of Tuberculosis and Lung Disease.* 2006;10(6):631–8.
 - 15.Mulu W, Mekkonen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. *African Health Sciences.* 2015 May 28;15(2):368.
 - 16.Li W-B, Zhang Y-Q, Xing J, Ma Z-Y, Qu Y-H, Li X-X. Factors associated with primary transmission of multidrug-resistant tuberculosis compared with healthy controls in Henan Province, China. *Infectious Diseases of Poverty.* 2015;4(1):14.
 - 17.Tadesse F. Risk Factors for Multi-drug Resistant Tuberculosis in Addis Ababa, Ethiopia. *Universal Journal of Public Health.* 2015;3(2):65–70.
 - 18.Baliza M, Bach AH, Queiroz GL de, Melo IC, Carneiro MM, Albuquerque M de FPM, et al. High frequency of resistance to the drugs isoniazid and rifampicin among tuberculosis cases in the city of Cabo de Santo Agostinho, an urban area in northeastern Brazil. *Revista da Sociedade Brasileira de Medicina Tropical.* 2008;41(1):11–6.